Thank you for your interest in clinical trials for Prostate Cancer in Anchorage. Use our Clinical Trials Search to find clinical trials for other conditions or locations.
Your search returned no results. Get alerts when studies become available.
Your search returned 7 studies:A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate CanceConditions: Castration-Resistant Prostate CancerLocation: Anchorage, AlaskaA Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer Conditions: Metastatic Hormone Sensitive Prostate CancerLocation: Anchorage, AlaskaEfficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)Conditions: Prostate Cancer Non-Metastatic - Castration-ResistantLocation: Anchorage, AlaskaSafety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)Conditions: Hormone Sensitive Prostate Cancer - Prostate Cancer - Cancer of the ProstateLocation: Anchorage, AlaskaObservational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)Conditions: Prostate Cancer - Castration-resistant Prostate Cancer - Metastatic Prostate CancerLocation: Anchorage, AlaskaA Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillanceConditions: Prostate CancerLocation: Anchorage, AlaskaAndrogen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerConditions: Prostate CancerLocation: Anchorage, Alaska
Didn't find what you were looking for? Try these alternatives:
ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.
ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.